Form 4: Adaptive Biotechnologies Director Acquires Shares and Options

Robert Hershberg, a director at Adaptive Biotechnologies, acquired shares and stock options on March 4, 2025, according to a Form 4 filing.

Summary

• On March 4, 2025, Robert Hershberg, a director of Adaptive Biotechnologies Corp, acquired 15,394 shares of common stock at $0.
• Following the transaction, Hershberg directly owns 122,690 shares.
• Hershberg also acquired options to purchase 23,726 shares of common stock at an exercise price of $8.12, which vest in equal monthly installments over one year from March 4, 2025, and expire on March 4, 2035.
• After the transaction, Hershberg directly owns 23,726 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares and options suggests confidence, but it's a routine transaction.

Positives

• A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The stock options vest monthly over one year from March 4, 2025, subject to continued service as a director.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates